{"changes":[{"companyHref":"/c/maplighttherapeutics-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml","domain":"maplighttherapeutics.com","fact":"latest round","name":"MapLight Therapeutics, Inc.","new":{"amountUsd":188187915,"date":"2025-07-28","lead":null,"type":null},"old":{"amountUsd":188187915,"date":"2025-07-28","lead":null,"type":"seed"},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"maplighttherapeutics-com","status":"sourced","url":"https://whoraisedwhat.com/c/maplighttherapeutics-com"},{"companyHref":"/c/maplighttherapeutics-com","date":"2026-09-25","documentUrl":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml","domain":"maplighttherapeutics.com","fact":"provenance:round","name":"MapLight Therapeutics, Inc.","new":{"publisher":"SEC EDGAR","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml"},"old":{"publisher":"sec-edgar","status":"attributed","url":null},"publisher":"SEC EDGAR","reason":null,"retrievedAt":"2026-09-25","slug":"maplighttherapeutics-com","status":"sourced","url":"https://whoraisedwhat.com/c/maplighttherapeutics-com"}],"country":"US","description":"MapLight Therapeutics develops small-molecule CNS drugs, led by ML-007C-MA, an M1/M4 muscarinic agonist co-formulated with a peripheral anticholinergic to limit side effects. It treats schizophrenia (Phase 2 readout 2H26) and Alzheimer's disease psychosis. MapLight synchronizes agonist and antagonist pharmacokinetics to dampen side effects.","domain":"maplighttherapeutics.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":37.486324,"lng":-122.232523,"location":"REDWOOD CITY, CA","name":"MapLight Therapeutics, Inc.","rounds":[{"amountQuarantined":false,"amountUsd":188187915,"currency":"USD","date":"2025-07-28","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml"},"status":"sourced","type":null,"url":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml"}],"slug":"maplighttherapeutics-com","sources":[{"fact":"round","publisher":"SEC EDGAR","retrievedAt":"2026-09-25","status":"sourced","url":"https://www.sec.gov/Archives/edgar/data/1770069/000123191925000129/primary_doc.xml"},{"fact":"existence","publisher":"maplighttherapeutics.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://maplighttherapeutics.com"},{"fact":"description","publisher":"maplighttherapeutics.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://maplighttherapeutics.com"}],"stage":null,"techStack":[],"totalRaisedUsd":188187915,"updatedAt":"2026-05-05"}